This has been shown with antibody targeting of CD38 with daratumumab and isatixumab, and of SLAMF7 with elotuzumab, which were well-tolerated in patients with newly diagnosed and relapsed/refractory MM (37–39). Here, SLAMF7 is linked to Miyoshi myopathy.